These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 37768417)

  • 1. Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice.
    Ilagan-Ying YC; Banini BA; Do A; Lam R; Lim JK
    Curr Gastroenterol Rep; 2023 Oct; 25(10):213-224. PubMed ID: 37768417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.
    Kouvari M; Valenzuela-Vallejo L; Guatibonza-Garcia V; Polyzos SA; Deng Y; Kokkorakis M; Agraz M; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; George J; Mingrone G; Mantzoros CS
    Metabolism; 2023 Oct; 147():155666. PubMed ID: 37527759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    ; ;
    Obes Facts; 2024; 17(4):374-444. PubMed ID: 38852583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
    ; ; ;
    J Hepatol; 2024 Sep; 81(3):492-542. PubMed ID: 38851997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review.
    Wattacheril JJ; Abdelmalek MF; Lim JK; Sanyal AJ
    Gastroenterology; 2023 Oct; 165(4):1080-1088. PubMed ID: 37542503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NAFLD (MASLD)/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review.
    Sergi CM
    Int J Mol Sci; 2024 Aug; 25(15):. PubMed ID: 39126031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD.
    Abdelhameed F; Kite C; Lagojda L; Dallaway A; Chatha KK; Chaggar SS; Dalamaga M; Kassi E; Kyrou I; Randeva HS
    Curr Obes Rep; 2024 Sep; 13(3):510-531. PubMed ID: 38809396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.
    ; ;
    Diabetologia; 2024 Nov; 67(11):2375-2392. PubMed ID: 38869512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases.
    Sandireddy R; Sakthivel S; Gupta P; Behari J; Tripathi M; Singh BK
    Front Cell Dev Biol; 2024; 12():1433857. PubMed ID: 39086662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: A joint position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Hepatology (SBH), and Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso).
    Moreira RO; Valerio CM; Villela-Nogueira CA; Cercato C; Gerchman F; Lottenberg AMP; Godoy-Matos AF; Oliveira RA; Brandão Mello CE; Álvares-da-Silva MR; Leite NC; Cotrim HP; Parisi ER; Silva GF; Miranda PAC; Halpern B; Pinto Oliveira C
    Arch Endocrinol Metab; 2023 Nov; 67(6):e230123. PubMed ID: 38048417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes.
    Younossi ZM; Golabi P; Price JK; Owrangi S; Gundu-Rao N; Satchi R; Paik JM
    Clin Gastroenterol Hepatol; 2024 Oct; 22(10):1999-2010.e8. PubMed ID: 38521116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
    Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
    Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and Emerging Biomarkers and Imaging Modalities for Nonalcoholic Fatty Liver Disease: Clinical and Research Applications.
    Hydes T; Brown E; Hamid A; Bateman AC; Cuthbertson DJ
    Clin Ther; 2021 Sep; 43(9):1505-1522. PubMed ID: 34400007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of current knowledge and non-invasive testing modalities for predicting at-risk non-alcoholic steatohepatitis and assessing fibrosis.
    Kugelmas M; Noureddin M; Gunn N; Brown K; Younossi Z; Abdelmalek M; Alkhouri N
    Liver Int; 2023 May; 43(5):964-974. PubMed ID: 36864668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic dysfunction associated steatotic liver disease: Current practice, screening guidelines and management in the primary care setting.
    Gupta U; Ruli T; Buttar D; Shoreibah M; Gray M
    Am J Med Sci; 2024 Feb; 367(2):77-88. PubMed ID: 37967750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease.
    Wang SW; Hsieh TH; Cheng YM; Wang CC; Kao JH
    Hepatol Int; 2024 Jun; 18(3):943-951. PubMed ID: 38227142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease.
    Kanwal F; Neuschwander-Tetri BA; Loomba R; Rinella ME
    Hepatology; 2024 May; 79(5):1212-1219. PubMed ID: 38445559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease.
    Noureddin N; Copur-Dahi N; Loomba R
    Aliment Pharmacol Ther; 2024 Jun; 59 Suppl 1(Suppl 1):S41-S51. PubMed ID: 38813822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-invasive testing and risk-stratification in patients with MASLD.
    Zoncapè M; Liguori A; Tsochatzis EA
    Eur J Intern Med; 2024 Apr; 122():11-19. PubMed ID: 38246813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endoscopic sleeve gastroplasty for metabolic dysfunction-associated steatotic liver disease.
    Matteo MV; Gualtieri L; Bove V; Palumbo G; Pontecorvi V; De Siena M; Barbaro F; Spada C; Boškoski I
    Expert Rev Gastroenterol Hepatol; 2024 Aug; 18(8):397-405. PubMed ID: 39234763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.